ArticleWorld journal of microbiology & biotechnology2026
Purification and mechanistic characterisation of bacillomycin D homologues from Bacillus velezensis PD9 with antibiofilm activity against methicillin-resistant Staphylococcus aureus.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antimicrobial resistance continues to undermine treatment of multidrug-resistant infections, necessitating new antimicrobial agents with distinct mechanisms of action. Bacillus velezensis PD9 (BvPD9), isolated from Heterotrigona itama propolis, produces antibacterial lipopeptides; however, the active bacillomycin D homologues and their mechanisms remain insufficiently characterised. Here, an optimised extraction and chromatographic purification workflow was developed, enabling selective enrichment of two bioactive fractions putatively assigned by LC-TOF-MS/MS as C14-enriched bacillomycin D and a C14/C15-bacillomycin D homologue mixture. The C14-enriched bacillomycin D fraction exhibited selective activity against Staphylococcus spp. and vancomycin-sensitive Enterococcus faecium (VSEF), with minimum inhibitory concentrations (MICs) of 16-32 µg/mL, whereas the C14/C15 homologue mixture demonstrated broader antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and selected ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) (MICs 16-512 µg/mL), with the lowest MIC (16 µg/mL) observed against VSEF. Both compounds retained activity following heat exposure (40-80 °C), wide pH variation (4-12), and proteolytic enzymes. The C14/C15 homologue mixture was prioritised for further evaluation because of its broader antibacterial spectrum and displayed concentration-dependent inhibition of biofilm formation, membrane permeabilisation, and ultrastructural alterations, together with changes in bacterial DNA-content distribution without detectable direct DNA binding. Preliminary safety evaluation demonstrated concentration-dependent haemolysis and cytotoxicity at higher concentrations, while zebrafish embryos showed concentration-dependent mortality with an LC
Indexed as
Identifiers
42905192What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.